Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by contacting Pomerantz LLP [1][2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Ultragenyx and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Ultragenyx securities during the Class Period [2]. Group 2: Stock Performance and Events - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to achieve statistical significance, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5].

Group 1 - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices [2] - Investors who purchased Ultragenyx securities during the Class Period have until April 6, 2026, to request appointment as Lead Plaintiff [2] - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate and securities class litigation [6] Group 2 - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4] - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to meet primary endpoints, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Ultragenyx and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Ultragenyx securities during the Class Period [2]. Group 2: Stock Performance and Events - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to achieve statistical significance, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices related to the company's clinical trial results and stock price decline [1]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Mereo and certain officers/directors engaged in securities fraud or other unlawful business practices [1]. - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to request to be appointed as Lead Plaintiff [1]. Group 2: Clinical Trial Results - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced that the Phase 3 Orbit study was progressing toward a final analysis, which led to a 42.52% drop in Mereo's ADR price, closing at $1.69 per share on July 10, 2025 [1]. - On December 29, 2025, Mereo announced that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in an 87.7% decline in ADR price, closing at $0.29 per ADR [1].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by April 6, 2026 [1]. Company Developments - On July 9, 2025, Ultragenyx and Mereo BioPharma Group announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [1]. - Following this announcement, Ultragenyx's stock price dropped by $10.41, or 25.11%, closing at $31.04 on July 10, 2025 [1]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in their primary endpoints, leading to a further stock price decline of $14.47, or 42.32%, closing at $34.19 [1]. Legal Context - The class action lawsuit is focused on whether Ultragenyx and its executives engaged in fraudulent activities that misled investors [1]. - Pomerantz LLP, the law firm handling the case, has a history of successful litigation in securities fraud and corporate misconduct cases [1].

Corporate Presentation February 2026 Confidential and Proprietary Forward looking statements Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations, estimates, assumptions, and projections regarding our future operating results and financial performance, including our expectations for profitability in 2027, anticipated cost or expense management, including the company's expectations rel ...

Core Insights - Ultragenyx Pharmaceutical reported a third-quarter 2025 loss of $1.81 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.23, and compared to a loss of $1.40 per share in the same quarter last year [1][6] - Total revenues for the quarter were $159.9 million, reflecting a 15% year-over-year increase, but fell short of the Zacks Consensus Estimate of $168 million [1][6] Revenue Breakdown - Crysvita generated total revenues of $111.9 million, up 14% year over year, with contributions of $57 million from North America, $47 million from Latin America and Turkey, and $8 million from Europe [4] - Mepsevii product revenues declined by 27% year over year to $7 million, while Dojolvi revenues increased by 14% to $24.3 million due to new patient demand [5] - Evkeeza recorded sales of $16.7 million, up 57% as the drug continues to be launched in territories outside the United States [5][6] Operating Expenses - Operating expenses for the quarter were $330.8 million, a 22% increase year over year, driven by higher investments in late-stage pipeline programs and marketing costs [8] - Research and development expenses were $216.2 million (up 27%), selling, general and administrative expenses were $86.6 million (up 8%), and cost of sales was $28 million (up 33%) [8] Financial Guidance - The company expects total revenues in 2025 to be between $640 million and $670 million, representing growth of approximately 14-20% compared to 2024 [10] - Crysvita revenues are projected to be in the range of $460-$480 million (up 12-17% year over year), while Dojolvi revenues are expected between $90 million and $100 million (up 2-14% year over year) [10] Pipeline Updates - Ultragenyx faced a setback with the FDA issuing a complete response letter for its biologics license application for UX111, requesting more information related to manufacturing [12] - The company plans to resubmit the BLA for UX111 early in 2026 [13] - GTX-102 received Breakthrough Therapy designation from the FDA for treating Angelman syndrome, with data expected in the second half of 2026 [14] - The company has begun the rolling submission of a BLA for its investigational gene therapy DTX401, expected to be completed in Q4 2025 [15]

Core Insights - Ultragenyx Pharmaceutical reported a second-quarter 2025 loss of $1.17 per share, which is an improvement from a loss of $1.52 per share in the same quarter last year and better than the Zacks Consensus Estimate of a loss of $1.27 [1][5] - Total revenues for the quarter reached $166.5 million, reflecting a 13% year-over-year increase, driven primarily by higher product sales, and surpassing the Zacks Consensus Estimate of $162 million [1][5] Revenue Breakdown - Crysvita generated total revenues of $120.4 million, up 6% year over year, with contributions of $79 million from North America, $35 million from Latin America and Turkey, and $7 million from Europe [3] - Mepsevii product revenues increased by 35% year over year to $8.3 million, while Dojolvi revenues rose 20% to $23.2 million due to new patient demand [4] - Evkeeza recorded sales of $14.6 million in the first quarter, showing significant growth as the drug continues to be launched in territories outside the United States [4] Financial Guidance - The company reaffirmed its 2025 financial guidance, expecting total revenues between $640 million and $670 million, which represents a growth of approximately 14-20% compared to 2024 [9] - Crysvita revenues are anticipated to be in the range of $460-$480 million, reflecting a year-over-year increase of 12-17%, while Dojolvi revenues are expected to be between $90 million and $100 million, up 2-14% year over year [9] Operating Expenses - Operating expenses for the quarter were $274.4 million, a 4% increase year over year, attributed to higher investments in late-stage pipeline programs and marketing costs for approved drugs [7] - Research and development expenses were $164.7 million (up 2%), selling, general and administrative expenses were $86.6 million (up 7%), and cost of sales was $23 million (up 8%) [7] Pipeline Updates - The FDA issued a complete response letter for Ultragenyx's biologics license application for UX111, requesting additional information related to manufacturing processes, which the company plans to address promptly [11][12] - The company is also developing GTX-102 for Angelman syndrome, which received Breakthrough Therapy designation, with data expected in the second half of 2026 [14] - Ultragenyx plans to submit a BLA for DTX401, a gene therapy for glycogen storage disease type Ia, in the fourth quarter of 2025 [15]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced the progress of the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [2] - Following the announcement, Mereo's ADR price dropped by $1.25, or 42.52%, closing at $1.69 per share on July 10, 2025 [2] Group 2 - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having pioneered the field of securities class actions over 80 years ago [3] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]